Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Substituted phenethylamineamphetamine, methamphetamine, cocaine +2 moreamphetamine, methamphetamine, cocaine, MDMA, other dopaminergic stimulants show less
4-FMA
4-fluoromethamphetamine
4-FMA (4-fluoromethamphetamine) is a synthetic stimulant of the substituted amphetamine class. It is the N-methyl structural analog of 4-FA, with more pronounced emotional warmth. It floods the brain with dopamine, serotonin, and norepinephrine simultaneously,[1] producing a hybrid stimulant-entactogen effect.
4-FMA (4-fluoromethamphetamine) is a synthetic stimulant of the substituted amphetamine class. It is the N-methyl structural analog of 4-FA, distinguished by more pronounced entactogenic character. 4-FMA is a triple monoamine releasing agent, producing its effects by driving simultaneous release of dopamine, serotonin, and norepinephrine.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
Substituted phenethylamineamphetamine, methamphetamine, cocaine +2 moreamphetamine, methamphetamine, cocaine, MDMA, other dopaminergic stimulants show less
4-FMA first appeared on Japanese research chemical markets around 2006, with no documented discoverer or first synthesis.[2] When the Netherlands scheduled 4-FA in 2017, 4-FMA rapidly replaced it as a legal substitute — a documented case of one ban creating demand for a less-studied compound.[3] It now circulates internationally and has been detected in seizures across Europe, North America, and East Asia.
Subjective effects include euphoria, empathy enhancement, sociability enhancement, stimulation, and focus enhancement.[4] The experience sits between MDMA's emotional warmth and methamphetamine's driven energy — prosocial openness and physical activation in one state.[1] Jaw tension, insomnia, and a low-mood crash in the days that follow are common unsought effects.
Dependence liability is moderate, and the most characterized physical danger is liver toxicity that can strike unpredictably regardless of dose.[5] The liver risk is shaped by genetic variation in drug-metabolizing enzymes — some people produce more toxic breakdown products than others, and alcohol worsens this.[5] Only three published studies exist — no human trials, no controlled safety data — making the true risk profile largely unknown.[4]
History[edit]
Discovery
4-FMA first appeared as a research chemical sold in Japan around 2006.[2] No discoverer or first synthesis date has been identified. The compound appears in no classic pharmacological references; forensic reference standards became commercially available from multiple analytical suppliers.[2]
International detection and spread
International detections emerged around 2012, with seizures reported from Canada, Spain, Finland, Ireland, and the United States.[2] In Taiwan, 4-FMA appeared in postmortem cases between 2011 and 2018, typically alongside other substances.[6] Korean forensic labs confirmed it in urine samples from novel psychoactive substance users by 2018.[7]
Regulatory displacement from 4-FA
The biggest shift came when the Netherlands scheduled 4-FA in 2017. By 2018, samples submitted to Dutch drug-checking services as "4-FA" increasingly contained 4-FMA instead.[3][2] This represents a documented case of regulatory displacement: scheduling one substance pushed users toward a less-characterized structural analog.[3]
The name "4-FMA" follows standard research chemical nomenclature: "4" marks the para position of the fluorine atom on the phenyl ring, "F" for fluorine, "MA" for methamphetamine. Party pills sold by the Israeli company Neorganics were initially attributed to 4-FMA, but the active ingredient was later identified as the positional isomer 2-fluoromethamphetamine (2-FMA).[2] 4-FMA has no established street names and circulates almost exclusively under its alphanumeric designation.
Chemistry[edit]
Structural class
4-FMA belongs to the substituted amphetamine family within the broader phenethylamine class. Its core structure is methamphetamine with a fluorine atom added at the para (4-) position of the phenyl ring. That single modification significantly boosts serotonin release relative to methamphetamine, while preserving its dopaminergic and noradrenergic activity.[1]
4-FMA is also the N-methyl structural analog of 4-fluoroamphetamine (4-FA) — the extra methyl group on the nitrogen mirrors the relationship between methamphetamine and amphetamine. This increases the compound's fat solubility and brain penetration relative to 4-FA.
Molecular properties
| Molecular formula | C₁₀H₁₄FN |
| Molecular weight | 167.22 g/mol |
Pharmacology[edit]
Mechanism of action
4-FMA enters monoamine nerve terminals through dopamine, serotonin, and norepinephrine transporters and reverses their normal direction — flooding the synapse with all three simultaneously. This mechanism was directly confirmed in lab models expressing human monoamine transporters.[1]
The distinguishing feature from methamphetamine is the fluorine atom, which boosts serotonin release to levels comparable to MDMA.[1] This places 4-FMA pharmacologically between a pure stimulant and a prototypical entactogen — more emotional warmth than methamphetamine, more driven energy than MDMA.
Pharmacokinetics
No human pharmacokinetic data exist. A lab study found that the liver enzyme CYP2E1 generates toxic 4-FMA breakdown products, while CYP2D6 and CYP3A4 neutralize them.[5] People who genetically produce less CYP2D6 — roughly 7–10% of those with European ancestry — may accumulate toxic byproducts at doses tolerated by others.[5]
Neuroscience[edit]
Where it acts
4-FMA's dopamine release targets the brain's reward circuit — from the ventral tegmental area to the nucleus accumbens — producing the euphoria and motivational drive characteristic of stimulants. Animal studies confirm that 4-FMA engages the same circuits as methamphetamine.[8]
The serotonin-releasing component — comparable in scale to MDMA[1] — reduces threat-related brain activity and promotes emotional openness. Norepinephrine release drives physical activation: raised heart rate, pupil dilation, wakefulness, and heightened alertness.
Why it matters
Dopamine drives "wanting" — craving and the compulsive redosing urge. Serotonin shifts the balance toward "liking" — satisfaction with what is already experienced. 4-FMA's dual profile may produce more moderate redosing urges than pure methamphetamine,inferred though this remains untested in controlled studies.
Key unknowns include whether 4-FMA produces the serotonin nerve terminal damage seen with MDMA, the dopamine neurotoxicity characteristic of methamphetamine, or some novel pattern. The para-fluorine may modify the metabolic pathways responsible for nerve terminal injury, but no neurotoxicity studies have been conducted in any species.
Subjective Effects[edit]
At common doses, 4-FMA produces a hybrid state: physical energy and mental clarity alongside emotional warmth and prosocial openness. Social settings draw out the entactogenic quality — emotional ease, empathy, and communicative flow. Solitary or task-focused settings bring the stimulant dimension forward. The post-acute period carries a monoamine-depletion signature: fatigue, low mood, and irritability that scale with dose.
4-FMA sits between MDMA and methamphetamine.[1] Compared to MDMA, it delivers more driven energy with less sedation. Compared to methamphetamine, it carries greater emotional warmth and prosocial character. This intermediate position is unusual and sparsely characterized among stimulant-entactogen compounds.
4-FMA surfaced on Japanese research chemical markets around 2006 as a novel psychoactive substance with no documented first synthesis.[2] Its prevalence expanded sharply after the Netherlands scheduled 4-FA in 2017, making 4-FMA the primary legal substitute in a documented case of regulatory displacement.[3] It now circulates internationally on research chemical markets and has been detected in drug seizures across Europe, North America, and East Asia.
Subjective effects include euphoria, empathy enhancement, sociability enhancement, stimulation, and focus enhancement.[4] The experience occupies an intermediate zone between MDMA's emotional warmth and methamphetamine's driven energy — a hybrid state colored by prosocial openness and physical activation.[1] Jaw tension, insomnia, and post-acute dysphoria are common unsought effects.
Dependence liability is rated moderate by class inference, and no lethal dose has been established in any species.[4] The primary characterized risk is liver toxicity driven by individual variation in drug-metabolizing enzymes, meaning adverse reactions can occur unpredictably and independently of dose.[5] Three published studies constitute the entire evidence base — no human trials, no controlled pharmacokinetic data, and no systematic safety monitoring exist.
History[edit]
Discovery
4-FMA first appeared in commerce as a research chemical sold in Japan around 2006.[2] No specific discoverer or first synthesis date has been identified in the scientific literature, and the compound does not appear in classic pharmacological reference works such as Shulgin's PiHKAL. It is classified as a novel psychoactive substance originating entirely in the research chemical era, with forensic reference standards now available from multiple analytical suppliers.[2]
International detection and spread
International detections surfaced in Europe and North America by approximately 2012, with seizures reported to the UNODC from Canada, Spain, Finland, Ireland, and the United States.[2] In Taiwan, 4-FMA appeared in postmortem specimens from fatal cases between 2011 and 2018, typically alongside other substances.[6] Korean forensic laboratories confirmed the compound in urine samples from novel psychoactive substance users by 2018.[7]
Regulatory displacement from 4-FA
The most significant expansion in 4-FMA's market presence followed the scheduling of 4-FA in the Netherlands in 2017. Because 4-FMA shares a similar name and reportedly similar effects, it gained rapid popularity as a legal substitute — by 2018, increasing proportions of samples submitted as "4-FA" to Dutch drug-checking services contained 4-FMA instead.[3][2]
This pattern represents a documented case of regulatory displacement, where scheduling one substance drives market substitution to a closely related unscheduled structural analog, with direct consequences for users who unknowingly consume a less-characterized compound.[3]
The name "4-FMA" follows standard research chemical nomenclature: "4" denotes the para position of the fluorine atom on the phenyl ring, "F" for fluorine, and "MA" for methamphetamine. Early confusion surrounded the compound's identity — party pills marketed by the Israeli company Neorganics were initially attributed to 4-FMA, but the active ingredient was later identified as the positional isomer 2-fluoromethamphetamine (2-FMA).[2] 4-FMA has no established street names and circulates almost exclusively under its alphanumeric designation.
Chemistry[edit]
Structural class
4-FMA belongs to the substituted amphetamine family within the broader phenethylamine class. Its parent scaffold is methamphetamine, modified by a fluorine atom at the para (4-) position of the phenyl ring. This para-fluorine substitution is the defining structural feature: it enhances serotonergic activity relative to the unsubstituted parent compound while retaining dopaminergic and noradrenergic release properties.[1]
4-FMA is the N-methyl structural analog of 4-fluoroamphetamine (4-FA) — the additional methyl group on nitrogen mirrors the relationship between methamphetamine and amphetamine. This modification typically increases fat solubility, brain penetration, and metabolic stability.
Molecular properties
| Molecular formula | C₁₀H₁₄FN |
| Molecular weight | 167.22 g/mol |
Stereochemistry
4-FMA has a single chirality center, producing (R)- and (S)-enantiomers. Commercially available 4-FMA is sold as a racemic mixture.[2] By analogy with methamphetamine — where the (S)-(+)-enantiomer carries substantially greater potency — the (S)-enantiomer of 4-FMA is predicted to be the more pharmacologically active form, though this remains unconfirmed.inferred
Structure-activity relationships
Within the fluorinated amphetamine series, the position of the fluorine atom on the phenyl ring determines pharmacological character. The para (4-) position uniquely confers the strongest shift toward serotonergic activity, distinguishing 4-FMA from its 2- and 3-fluorine positional isomers.[1] The N-methyl group increases lipophilicity and central nervous system penetration relative to the primary amine 4-FA.
Physical properties
No melting point, boiling point, or solubility data have been published for 4-FMA. The free base is expected to be a liquid or low-melting oil; the hydrochloride salt is the form most commonly encountered on research chemical markets.inferred
Pharmacology[edit]
Mechanism of action
4-FMA enters monoamine nerve terminals through the norepinephrine, dopamine, and serotonin transporters, then reverses their normal direction — flooding the synapse with all three neurotransmitters simultaneously. This mechanism was directly characterized in laboratory cell models expressing human monoamine transporters.[1]
The critical distinction from its parent compound methamphetamine is the enhanced serotonin release conferred by the para-fluorine substitution. 4-FMA releases serotonin at levels comparable to MDMA, producing a more balanced profile between dopaminergic stimulation and serotonergic warmth.[1] This positions 4-FMA pharmacologically between a pure stimulant (methamphetamine) and a prototypical entactogen (MDMA).
4-FMA also shows affinity for the 5-HT₂A serotonin receptor and TAAR1 (TAAR1), which may contribute additional modulatory effects on mood and monoamine signaling.[1] No activation of the 5-HT₂B receptor — associated with cardiac valve damage in chronic serotonergic drug use — was observed.
Pharmacokinetics
No human pharmacokinetic studies have been published for 4-FMA. Peak blood levels, half-life, bioavailability, and protein binding remain entirely uncharacterized in humans.
Metabolism has been partially explored in laboratory hepatocyte models.[5] The enzyme CYP2E1 generates toxic metabolites from 4-FMA, while CYP2D6 and CYP3A4 serve protective detoxification roles. Individuals who are genetically poor CYP2D6 metabolizers (roughly 7–10% of European-descent populations) may accumulate toxic byproducts at lower doses than the general population.[5]
The closest human pharmacokinetic reference comes from studies on 4-FA, where urinary metabolite concentrations peaked approximately 4 hours after ingestion.[8] Whether 4-FMA follows a similar metabolic pathway — including possible conversion to 4-FA as a breakdown product — has not been established.
Neuroscience[edit]
Where it acts
4-FMA's dopamine release targets the mesolimbic mesolimbic pathway — from the ventral tegmental area to the nucleus accumbens — producing the acute euphoria and motivational drive characteristic of stimulants. Anchondo et al. confirmed engagement of these reward circuits by demonstrating that 4-FMA fully substitutes for methamphetamine in trained animal discrimination tests.[9]
The serotonin-releasing component, comparable in magnitude to MDMA,[1] is expected to reduce threat-related activity in the amygdala and enhance prefrontal-amygdala communication — neural patterns that underlie the prosocial warmth, empathy enhancement, and emotional openness reported by users. Norepinephrine release drives the physical activation: elevated heart rate, pupil dilation, wakefulness, and heightened vigilance.
Why it matters
4-FMA's dual dopaminergic-serotonergic profile maps onto a distinction between "wanting" (dopamine-driven craving and motivation) and "liking" (hedonic satisfaction). Pure stimulants like methamphetamine predominantly amplify wanting, which drives compulsive redosing; 4-FMA's serotonergic component may shift the balance toward satisfaction with reduced compulsive drive.inferred
This is consistent with reports of more moderate redosing urges relative to methamphetamine, though the hypothesis remains untested in controlled studies.
Key unknowns include whether 4-FMA produces the serotonin terminal damage seen with MDMA, the dopaminergic neurotoxicity characteristic of methamphetamine, or some novel pattern — the para-fluorine may modify the metabolic pathways responsible for nerve terminal injury, but no neurotoxicity studies have been conducted in any species.
Subjective Effects[edit]
The 4-FMA experience is shaped substantially by dose and social context. At common doses, the compound produces a hybrid stimulant-entactogen state: physical energy and mental sharpness coexist with emotional warmth, prosocial openness, and enhanced tactile awareness. Social environments tend to amplify the entactogenic dimension, while solitary or task-oriented contexts foreground cognitive stimulation and focused energy. The post-acute phase carries a monoamine-depletion signature — fatigue, low mood, irritability — whose severity scales with dose and frequency.
Relative to MDMA, 4-FMA delivers more energetic stimulation with greater dopaminergic drive and less sedation; relative to methamphetamine, it provides greater emotional coloring and prosocial quality consistent with its enhanced serotonin release.[1] This intermediate positioning places 4-FMA in a sparsely characterized region of the stimulant-entactogen spectrum.
Effect Grid
At 50–75 mg oral, the hybrid stimulant-entactogen character of 4-FMA is fully expressed. Pronounced euphoria, empathy enhancement, sociability enhancement, and emotional openness emerge alongside physical stimulation, focus enhancement, and thought acceleration. Music enhancement and touch enhancement become noticeable. The experience occupies a middle ground between MDMA's entactogenic warmth and amphetamine's driven energy.
Physical effects are clearly present: appetite suppression is significant, pupil dilation is obvious, and bruxism, temperature dysregulation, and cardiovascular activation (elevated heart rate and blood pressure) become apparent. Excessive sweating and dehydration sensation may occur. Tactile euphoria and body high are commonly reported.
Sleep is impossible for approximately 6–8 hours after dosing. The post-acute phase typically involves fatigue, mild depression, irritability, and reduced motivation lasting 12–24 hours. Adequate hydration and temperature management are important at this dose level.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity enhancement · Sound sensitivity · Color enhancement · Tinnitus
Dry mouth · Pupil dilation · Body high · Dehydration sensation · Heart rate perception changes · Insomnia · Physical fatigue · Bodily lightness · Bruxism · Excessive sweating · Muscle tension · Restlessness · Tactile euphoria · Breathing alteration · Headache · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Constipation · Laughter fits · Nausea · Dizziness · Trembling · Motor control impairment · Vomiting
Dehydration sensation · Heart rate perception changes · Insomnia · Physical fatigue · Bodily lightness · Bruxism · Excessive sweating · Muscle tension · Restlessness · Tactile euphoria · Breathing alteration · Headache · Respiratory stimulation · Sexual arousal enhancement · Spontaneous body sensations · Tingling / electric sensations · Vibrations / buzzing · Motor control enhancement · Constipation · Laughter fits · Nausea · Dizziness · Trembling · Vomiting
Information processing enhancement · Motivation enhancement · Aesthetic enhancement · Cognitive fatigue · Pattern recognition enhancement · Analysis enhancement · Cognitive flexibility · Conceptual thinking · Introspection enhancement · Language enhancement · Openness enhancement · Thought connectivity · Thought organization · Creativity enhancement · Humor enhancement · Memory enhancement · Multiple thought streams · Cognitive dysphoria · Cognitive impairment · Confusion · Decision impairment · Thought disorganization · Thought loops · Delusions
Cognitive fatigue · Pattern recognition enhancement · Analysis enhancement · Cognitive flexibility · Conceptual thinking · Introspection enhancement · Language enhancement · Openness enhancement · Thought connectivity · Thought organization · Creativity enhancement · Humor enhancement · Memory enhancement · Multiple thought streams · Cognitive dysphoria · Cognitive impairment · Confusion · Thought disorganization · Thought loops · Delusions
Anhedonia · Anxiety · Irritability · Catharsis · Emotional lability · Simultaneous emotions · Anxiety suppression · Dysphoria · Mania
Catharsis · Emotional lability · Simultaneous emotions · Anxiety suppression · Dysphoria
Sociability enhancement · Disinhibition · Emotional susceptibility · Trust enhancement · Flow state · Ego inflation · Self-control enhancement · Depersonalization · Derealization
Flow state · Ego inflation · Self-control enhancement · Depersonalization · Derealization
Timeline
Initial awareness of effects — mild alertness increase, subtle body warmth, and a faint sharpening of attention. Effects may be difficult to distinguish from anticipation at this stage.
Progressive building of stimulation and entactogenic warmth. Euphoria, sociability, and physical energy emerge. Pupil dilation and mild appetite suppression begin.
Full expression of the hybrid stimulant-entactogen profile — maximal euphoria, empathy enhancement, sociability, focus enhancement, stimulation, and tactile enhancement. Cardiovascular effects most pronounced. Bruxism and temperature dysregulation peak.
Gradual reduction of stimulant and entactogenic effects. Mood begins to normalize, residual stimulation persists, and fatigue may emerge. Appetite starts returning.
Residual wakefulness, low-grade fatigue, and mood dipping below baseline. Appetite returns. Physical recovery proceeds gradually.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · cocaine
Toxicity
No lethal dose has been established for 4-FMA in any species. No human overdose deaths attributable solely to 4-FMA have been identified in the published literature.safety citation needed
Liver toxicity
Lab studies show 4-FMA damages liver cells through mitochondrial destabilization, oxidative stress, and triggering of cell death pathways.[5]
Cardiovascular toxicity
No substance-specific cardiovascular data exist for 4-FMA. Data from its close structural analog 4-FA indicate serious riskinferred: emergency department presentations involving 4-FA showed mean systolic blood pressure of 164 ± 31 mmHg — significantly higher than both MDMA and amphetamine — with severe headache in 80% of mono-intoxicated patients.[3]
Serious complications occurred in 40% of 4-FA mono-intoxications, including heart damage, brain hemorrhage, and dangerously elevated blood pressure.[3] All affected patients had no prior history of high blood pressure, indicating acute drug-induced effects.[3]
Serotonin toxicity
4-FMA releases serotonin at levels comparable to MDMA.[1] Combining it with other serotonergic drugs creates a pharmacologically grounded risk for serotonin syndrome — a potentially life-threatening condition involving extreme body temperature, rigid muscles, and seizures. No 4-FMA-specific cases have been reported, but the underlying mechanism is identical to MDMA-associated serotonin toxicity.inferred
Forensic findings
4-FMA was found in postmortem specimens from fatal cases in Taiwan between 2011 and 2018, frequently alongside ketamine and benzodiazepine metabolites.[6] Its individual contribution to those deaths could not be determined due to polydrug use. Standard amphetamine drug tests may not detect 4-FMA; specialized laboratory testing is required for definitive identification.[9]
Psychological risks
Anxiety, paranoia, and agitation can occur at higher doses or in predisposed individuals.inferred Prolonged wakefulness at high doses can produce hallucinations and delusional thinking. Post-acute dysphoria and low mood are expected consequences of monoamine depletion, analogous to the comedown characterized with MDMA and methamphetamine.
Tolerance and dependence
No tolerance or dependence studies specific to 4-FMA exist.inferred Tolerance builds through adaptations in DAT function and receptor sensitivity; cross-tolerance with other stimulants and MDMA is expected.[1] Animal studies show 4-FMA substitutes fully for methamphetamine,[8] consistent with comparable abuse potential. Community consensus rates both physical and psychological dependence as moderate.[4]
Drug Interactions
Monoamine oxidase inhibitors (MAOIs) represent the highest-severity interaction. They block serotonin breakdown while 4-FMA floods synapses with released serotonin, creating conditions for life-threatening serotonin syndrome and dangerous blood pressure spikes.safety citation needed Combining with tramadol is classified as lethal[4] — tramadol inhibits serotonin reuptake, adding to 4-FMA's serotonin release.safety citation needed
Other serotonergic drugs — SSRIs, SNRIs, triptans, lithium, linezolid — raise serotonin syndrome risk. Combining with PCP is classified as dangerous, likely reflecting additive central nervous system and cardiovascular stimulation.inferred Medications that inhibit CYP2D6 (fluoxetine, paroxetine, bupropion) or CYP3A4 (ketoconazole, grapefruit juice) impair the liver's protective detoxification pathways.[5] Alcohol increases CYP2E1 activity, shifting metabolism toward more toxic breakdown products.[5]
Combining 4-FMA with other stimulants adds cardiovascular risk; 4-FA analog data document blood pressure reaching severely elevated levels during intoxication.[3] Combining with depressants like GHB, alcohol, or ketamine may mask cardiovascular warning signs that would otherwise prompt medical attention.[6]
Contraindications
10 knownThe following contraindications are derived from 4-FMA's pharmacology and the safety profile of its structural analog 4-FA. No 4-FMA-specific contraindication studies exist.inferred
Absolute contraindications:
- Concurrent MAOI use — risk of dangerously elevated blood pressure and serotonin syndromesafety citation needed
- Concurrent tramadol use — additive serotonergic toxicity; classified as lethal in community databasessafety citation needed
Relative contraindications:
- Heart disease, high blood pressure, or history of stroke — 4-FA analog data demonstrate acute severe blood pressure elevation and brain hemorrhage at recreational doses[10][3]
- Liver disease — impaired detoxification may increase liver damage risk[5]
- CYP2D6 poor metabolizer status — reduced capacity to neutralize toxic 4-FMA breakdown products[5]
- Concurrent serotonergic medication (SSRIs, SNRIs, triptans, lithium, linezolid) — elevated serotonin syndrome risksafety citation needed
- Concurrent CYP2D6 or CYP3A4 inhibitors — impairment of protective metabolic pathways[5]
- History of seizures — stimulants may lower the seizure thresholdinferred
- Pregnancy — no reproductive data exist; cardiovascular and monoamine effects contraindicate useinferred
Harm Reduction[edit]
Forms & Identification
The primary concern is substitution. After the 2017 scheduling of 4-FA in the Netherlands, material sold as "4-FA" frequently contained 4-FMA instead.[3] The reverse is equally possible — 4-FMA purchases may contain other fluorinated amphetamines or unrelated substances.
Standard amphetamine immunoassay screens may not detect 4-FMA. Quantitative laboratory testing (LC-MS/MS or GC-MS) is required for definitive identification.[9] Reagent testing offers a useful first screen but cannot reliably distinguish between closely related fluorinated amphetamine isomers.
Guidelines
- Use a milligram-precision scale. Powder density varies, and individual metabolic differences (CYP2D6 status) mean the margin between a moderate and problematic dose differs between people.[5]
- Start with a low dose and allow a full 90 minutes before assessing whether effects have fully developed. Oral onset can be gradual.
- Do not redose. Each additional dose extends monoamine depletion and increases cardiovascular strain.
- Avoid alcohol, which increases CYP2E1 activity and may shift metabolism toward more toxic pathways.[5]
- Stay hydrated but do not overhydrate — serotonergic stimulants can impair the body's water regulation. Drink to thirst, not to a fixed schedule.
- Monitor for severe headache, the most common serious symptom in 4-FA emergency presentations (80% of cases).[3] Severe or sudden-onset headache warrants immediate medical evaluation.
Set & Setting
Social environments amplify 4-FMA's entactogenic qualities — emotional openness, empathy, and ease of communication. Solitary settings bring the stimulant dimension to the foreground. First-time use benefits from a calm, familiar environment with trusted companions.
Planning 24–48 hours of reduced activity afterward, with access to food, hydration, and a comfortable rest environment, reduces the impact of post-acute fatigue and low mood.
Aftercare & integration. The post-acute period involves temporary depletion of dopamine, serotonin, and norepinephrine. Expect 1–3 days of fatigue, low mood, irritability, and difficulty concentrating.
Prioritize sleep — stimulant effects may delay sleep onset, so avoid late-evening dosing. Nutritious meals, particularly those rich in protein and complex carbohydrates, support neurotransmitter replenishment. Light exercise after adequate rest can accelerate mood recovery. If low mood, emotional flatness, or anxiety persists beyond 5–7 days, consult a healthcare professional.
Recovery & Support
If 4-FMA use has become compulsive, frequent, or is causing problems in daily life, support is available. Stimulant dependence responds to behavioral interventions including cognitive behavioral therapy and contingency management.
SAMHSA National Helpline (US): 1-800-662-4357 (free, confidential, 24/7). International users can contact local addiction services or visit findtreatment.gov for directory resources. Peer support communities provide non-judgmental spaces for people working to change their relationship with stimulants.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Seek immediate help if any of the following occur: severe or sudden-onset headache (potential brain hemorrhage), chest pain or pressure, seizures, loss of consciousness, body temperature hot to the touch through clothing, confusion or inability to communicate, or rigid muscles with extremely high body temperature (potential serotonin syndrome).
Immediate steps
- Call emergency services immediately.
- Keep the person calm and in a cool, quiet environment.
- If unconscious but breathing, place in the recovery position (on their side).
- Do not induce vomiting.
- Do not restrain the person unless they are in immediate danger of harming themselves.
- Monitor breathing continuously until help arrives.
What to tell the dispatcher
State the substance name (4-FMA or "a fluorinated amphetamine"), the approximate amount taken, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
4-FMA is not scheduled by name in all jurisdictions, but its structural similarity to methamphetamine means it falls under structural analog provisions in several countries. The 2017 scheduling of 4-FA in the Netherlands drew regulatory attention toward 4-FMA as a documented substitute compound.[3]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not named in any DEA scheduling order. Likely covered under the Federal Analogue Act (21 U.S.C. § 813) as a structural analog of methamphetamine (Schedule II) when intended for human consumption. 4-FA was placed in Schedule I effective February 2026, but 4-FMA was not included[2]safety citation needed |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the 1977 MDA amendment as a methamphetamine analog; Schedule 1 possession and supply offense[2] |
| Germany | Anlage II (BtMG) | Scheduled since July 26, 2012; license required for manufacture, possession, import, export, purchase, or sale[2] |
| Canada | Controlled (CDSA) | Controlled since 1996 as a methamphetamine analog under the Controlled Drugs and Substances Act[2] |
| Australia | Schedule 9 (Prohibited substance) | Prohibited except for approved medical or scientific research[2] |
| Japan | Controlled (sale/distribution) | Sale and distribution prohibited since 2008; personal possession not specifically addressed[2] |
| Netherlands | Effectively banned (~2017) | 4-FA scheduling in 2017 indirectly curtailed legal sale; 4-FMA market expanded as a substitute before further regulatory action[3][2] |
| China | Controlled | Scheduled since October 2015[2] |
| Italy | Schedule I | Prohibited[2] |
| New Zealand | Schedule 3 | Controlled as amphetamine analog[2] |
Analog act considerations
In the United States, 4-FMA's legal status is ambiguous. The Federal Analogue Act (21 U.S.C. § 813) may treat it as controlled when intended for human consumption, given its structural similarity to methamphetamine (Schedule II) and the recently scheduled 4-fluoroamphetamine (Schedule I, effective February 2026).[2]
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · cocaine
Toxicity
No lethal dose has been established for 4-FMA in any species. No human overdose deaths attributable solely to 4-FMA have been identified in the published literature.safety citation needed
Liver toxicity
The only published substance-specific toxicity study demonstrates that 4-FMA damages liver cells in laboratory models through mitochondrial destabilization, oxidative stress, depletion of protective antioxidants, and triggering of cell death pathways.[5]
Cardiovascular toxicity
No substance-specific cardiovascular data exist for 4-FMA. Data from the closely related structural analog 4-FA indicate serious cardiovascular riskinferred: emergency department presentations involving 4-FA showed mean systolic blood pressure of 164 ± 31 mmHg — significantly higher than both MDMA and amphetamine — with severe headache in 80% of mono-intoxicated patients.[3]
Serious complications occurred in 40% of 4-FA mono-intoxications, including stress-induced heart damage, brain hemorrhage, and dangerously elevated blood pressure.[3] All patients presenting with high blood pressure had no prior history of the condition, indicating acute drug-induced effects.[3] The relevance to 4-FMA is underscored by the fact that post-2017 market substitution means some 4-FA clinical presentations may have actually involved 4-FMA exposure.
Serotonin toxicity
4-FMA's serotonin-releasing capacity — comparable to MDMA[1] — creates a pharmacologically grounded risk for serotonin syndrome when combined with other serotonergic agents. No 4-FMA-specific cases have been reported, but the underlying mechanism is identical to that responsible for MDMA-associated serotonin toxicity.inferred
Forensic findings
4-FMA was detected in postmortem specimens from fatal cases in Taiwan between 2011 and 2018, frequently alongside ketamine and benzodiazepine metabolites.[6] The individual contribution of 4-FMA to these deaths could not be determined due to polydrug use. Standard amphetamine drug tests may not reliably detect 4-FMA; specialized laboratory testing is required for definitive identification.[10]
Psychological risks
No controlled studies of 4-FMA's psychological effects have been published.inferred Acute psychological distress — including anxiety, paranoia, and agitation — is reported with stimulant-entactogen compounds, particularly at higher doses or in predisposed individuals.
The serotonergic component may contribute to emotional lability during the comedown phase. Prolonged wakefulness at high doses carries potential for temporary psychotic symptoms consistent with stimulant psychosis. Post-acute dysphoria and low mood are expected consequences of acute monoamine depletion, analogous to the comedown characterized with MDMA and methamphetamine.
Tolerance and dependence
No tolerance, dependence, or withdrawal studies specific to 4-FMA have been published.inferred Tolerance to stimulant and euphoric effects develops with repeated use through adaptations in DAT function and receptor sensitivity. Cross-tolerance with other dopaminergic stimulants (amphetamine, methamphetamine) and with MDMA is expected.[1]
Anchondo et al. demonstrated that 4-FMA fully substitutes for methamphetamine in trained animal discrimination tests,[9] consistent with abuse potential comparable to methamphetamine. Self-administration studies — the gold standard for quantifying addictive potential — have not been conducted. Community consensus rates both physical and psychological dependence as moderate.[4]
Drug Interactions
4-FMA's triple monoamine release with prominent serotonin activity creates two primary interaction risks: serotonergic overload and metabolic interference.
Monoamine oxidase inhibitors (MAOIs) represent the highest-severity interaction: by preventing serotonin breakdown while 4-FMA floods synapses with released serotonin, MAOIs create conditions for life-threatening serotonin syndrome and dangerous blood pressure spikes.safety citation needed The combination with tramadol is classified as lethal in community databases[4] — tramadol inhibits serotonin reuptake, creating additive serotonergic overload.safety citation needed
Other serotonergic combinations of concern include SSRIs, SNRIs, triptans, lithium, and linezolid. The combination with PCP is classified as dangerous, likely reflecting additive stimulation of the central nervous system and cardiovascular system.inferred
Medications that inhibit CYP2D6 (fluoxetine, paroxetine, bupropion) or CYP3A4 (ketoconazole, grapefruit juice) may impair 4-FMA's protective detoxification pathways, increasing toxic metabolite accumulation.[5] Alcohol increases CYP2E1 activity, potentially shifting metabolism toward more toxic byproducts.[5]
Co-administration with other stimulants carries additive cardiovascular risk. Given the severe blood pressure elevation documented with 4-FA (mean systolic 164 ± 31 mmHg in emergency presentations),[3] stacking additional stimulants is of particular concern. Combinations with depressants (GHB, alcohol, ketamine) may mask cardiovascular warning signs that would otherwise prompt medical attention.[6]
Contraindications
10 knownThe following contraindications are derived from 4-FMA's pharmacological mechanism and the safety profile of its structural analog 4-FA. No 4-FMA-specific contraindication studies exist.inferred
Absolute contraindications:
- Concurrent MAOI use — risk of dangerously elevated blood pressure and serotonin syndromesafety citation needed
- Concurrent tramadol use — additive serotonergic toxicity; classified as lethal in community databasessafety citation needed
Relative contraindications:
- Heart disease, high blood pressure, or history of stroke — 4-FA analog data demonstrate acute severe blood pressure elevation and brain hemorrhage at recreational doses[11][3]
- Liver disease — impaired detoxification may increase liver damage risk[5]
- CYP2D6 poor metabolizer status — reduced capacity to detoxify 4-FMA[5]
- Concurrent serotonergic medication (SSRIs, SNRIs, triptans, lithium, linezolid) — elevated serotonin syndrome risksafety citation needed
- Concurrent CYP2D6 or CYP3A4 inhibitors — impairment of protective metabolic pathways[5]
- History of seizures — stimulants may lower the seizure thresholdinferred
- Pregnancy — no reproductive data exist; class-level cardiovascular and monoamine effects contraindicate useinferred
Harm Reduction[edit]
Forms & Identification
The primary identification concern with 4-FMA is substitution. Following the 2017 scheduling of 4-FA in the Netherlands, material sold as "4-FA" frequently contained 4-FMA instead.[3] The reverse is equally possible — 4-FMA purchases may contain other fluorinated amphetamines or unrelated substances entirely.
Quantitative analysis through drug-checking services provides the most reliable identification. Standard amphetamine immunoassay screens may not detect 4-FMA; specialized laboratory testing (LC-MS/MS or GC-MS) is required for definitive confirmation.[10] Reagent testing offers a useful first-pass screen but cannot reliably distinguish between closely related fluorinated amphetamine isomers.
Guidelines
- Use a milligram-precision scale. Volumetric variations in powder density make eyeballing unreliable, and individual metabolic differences (CYP2D6 status) mean the margin between a moderate and problematic dose varies between people.[5]
- Start with a low dose and allow a full 90 minutes before considering whether effects have fully developed. Oral onset can be gradual.
- Avoid redosing. Each additional dose extends the duration of monoamine depletion and increases cardiovascular strain.
- Avoid alcohol, which increases CYP2E1 activity and may shift 4-FMA metabolism toward more toxic pathways.[5]
- Stay hydrated but avoid overhydration — serotonergic stimulants can impair the body's water regulation. Drink to thirst, not to a fixed schedule.
- Monitor for severe headache, which was the most common serious symptom in 4-FA emergency presentations (80% of cases).[3] Severe or sudden-onset headache warrants immediate medical evaluation.
Set & Setting
Social environments tend to amplify 4-FMA's entactogenic qualities — emotional openness, empathy, and communicative ease — while solitary settings foreground the stimulant dimension of focused energy and cognitive drive. First-time users benefit from a calm, familiar environment with trusted companions.
The post-acute comedown involves monoamine depletion. Planning for 24–48 hours of reduced activity afterward, with access to food, hydration, and a comfortable rest environment, reduces the impact of post-acute fatigue and low mood.
Aftercare & integration. The post-acute period following 4-FMA use involves temporary depletion of dopamine, serotonin, and norepinephrine. Expect 1–3 days of fatigue, low mood, irritability, and difficulty concentrating.
Prioritize sleep — the stimulant effects may delay sleep onset, so avoid late-evening dosing. Nutritious meals, particularly those rich in protein and complex carbohydrates, support neurotransmitter replenishment. Light exercise after adequate rest can accelerate mood recovery. If low mood, emotional flatness, or anxiety persists beyond 5–7 days, consider consulting a healthcare professional.
Recovery & Support
If 4-FMA use has become compulsive, frequent, or is causing problems in daily life, support is available. Stimulant dependence responds to behavioral interventions including cognitive behavioral therapy and contingency management.
SAMHSA National Helpline (US): 1-800-662-4357 (free, confidential, 24/7). International users can contact local addiction services or visit findtreatment.gov for directory resources. Peer support communities, both online and in-person, provide non-judgmental spaces for people working to change their relationship with stimulants.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency
Seek immediate help if any of the following occur: severe or sudden-onset headache (potential brain hemorrhage), chest pain or pressure, seizures, loss of consciousness, body temperature hot to the touch through clothing, confusion or inability to communicate, or rigid muscles with extremely high body temperature (potential serotonin syndrome).
Immediate steps
- Call emergency services immediately.
- Keep the person calm and in a cool, quiet environment.
- If unconscious but breathing, place in the recovery position (on their side).
- Do not induce vomiting.
- Do not restrain the person unless they are in immediate danger of harming themselves.
- Monitor breathing continuously until help arrives.
What to tell the dispatcher
State the substance name (4-FMA or "a fluorinated amphetamine"), the approximate amount taken, the time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
4-FMA occupies an inconsistent position in international drug scheduling frameworks. As a structural analog of both methamphetamine and 4-fluoroamphetamine, it falls under existing controlled substance definitions in several jurisdictions through analog provisions, while remaining unscheduled by name in others. The 2017 scheduling of 4-FA in the Netherlands catalyzed regulatory attention toward 4-FMA as a documented substitute compound.[3]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Not specifically scheduled | Not named in any DEA scheduling order. Likely covered under the Federal Analogue Act (21 U.S.C. § 813) as a structural analog of methamphetamine (Schedule II) when intended for human consumption. 4-FA was placed in Schedule I effective February 2026, but 4-FMA was not included[2]safety citation needed |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Controlled under the 1977 MDA amendment as a methamphetamine analog; Schedule 1 possession and supply offense[2] |
| Germany | Anlage II (BtMG) | Scheduled since July 26, 2012; license required for manufacture, possession, import, export, purchase, or sale[2] |
| Canada | Controlled (CDSA) | Controlled since 1996 as a methamphetamine analog under the Controlled Drugs and Substances Act[2] |
| Australia | Schedule 9 (Prohibited substance) | Prohibited except for approved medical or scientific research[2] |
| Japan | Controlled (sale/distribution) | Sale and distribution prohibited since 2008; personal possession not specifically addressed[2] |
| Netherlands | Effectively banned (~2017) | 4-FA scheduling in 2017 indirectly curtailed legal sale; 4-FMA market expanded as a substitute before further regulatory action[3][2] |
| China | Controlled | Scheduled since October 2015[2] |
| Italy | Schedule I | Prohibited[2] |
| New Zealand | Schedule 3 | Controlled as amphetamine analog[2] |
Analog act considerations
In the United States, 4-FMA's legal status is ambiguous. The Federal Analogue Act (21 U.S.C. § 813) provides that any substance "substantially similar" in chemical structure or pharmacological effect to a Schedule I or II controlled substance may be treated as controlled if intended for human consumption.
4-FMA is structurally similar to both methamphetamine (Schedule II) and the recently scheduled 4-fluoroamphetamine (Schedule I, effective February 2026), making analog act prosecution plausible but dependent on case-specific intent determination.[2]
Frequently asked questions
What is 4-FMA?
4-FMA is a synthetic substituted amphetamine that acts as a triple monoamine releasing agent with a balanced dopaminergic-serotonergic profile. First appearing on research-chemical markets circa 2006, it gained wider prevalence after the 2017 scheduling of 4-FA in the Netherlands.
How long does 4-FMA last?
Total duration by route of administration — Oral: 4 – 8 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for 4-FMA?
Psychedex publishes a dosage table for 4-FMA on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with 4-FMA?
The highest-severity documented interactions for 4-FMA: MAOIs (Lethal), 5-HTP, Tryptophan (Dangerous), Alpha-2 adrenergic receptor antagonist (Dangerous), Anticholinergics (Dangerous), Antihistamines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is 4-FMA addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for 4-FMA: tolerance builds moderate; full reset takes 10.5 days; cross-tolerance develops with amphetamine, methamphetamine, cocaine, MDMA, other dopaminergic stimulants. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1]
- [2]
- [3] ^abcdefghijklGresnigt FMJ, Snik A, Franssen EJF, Vanhommerig JW, de Lange DW, Riezebos RK (2022) 4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis — Journal of the American College of Emergency Physicians Open doi:10.1002/emp2.12813
- [4]
- [5]
- [6] ^abcYang CA, Liu HC, Liu RH, Lin DL, Wu SP (2022) Simultaneous Quantitation of Seven Phenethylamine-Type Drugs in Forensic Blood and Urine Samples by UHPLC-MS-MS — Journal of Analytical Toxicology doi:10.1093/jat/bkab014
references
- [1]
- [2]
- [3] ^abcdefghijklGresnigt FMJ, Snik A, Franssen EJF, Vanhommerig JW, de Lange DW, Riezebos RK (2022) 4-Fluoroamphetamine (4-FA) intoxication results in exaggerated blood pressure effects compared to MDMA and amphetamine: A retrospective analysis — Journal of the American College of Emergency Physicians Open doi:10.1002/emp2.12813
- [4]
- [5]
- [6] ^abcYang CA, Liu HC, Liu RH, Lin DL, Wu SP (2022) Simultaneous Quantitation of Seven Phenethylamine-Type Drugs in Forensic Blood and Urine Samples by UHPLC-MS-MS — Journal of Analytical Toxicology doi:10.1093/jat/bkab014